blood and urine

PreclinicalBiologic

CCentre Oscar Lambret

blood and urine is one of 22 biologic programs targeting Angiosarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngiosarcomaActive, not recruiting

AngiosarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Angiosarcoma

#DrugCompanyPhaseTrials

Halaven

Adriamycin

Taxol

6 4

Keytruda

Merck & Co.

Phase 2

3 5

Votrient

Novartis

Phase 2

2 6

Libtayo

Regeneron

Phase 2

1 7

Stivarga

Bayer

Phase 2

1 8

Nexavar

Bayer

Phase 2

1 9

TRC105

TTracon Pharmaceuticals Inc.

Phase 3

1 10

Avastin

BBio-Thera Solutions

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Angiosarcoma1 trial

Identification, Molecular Epidemiology Angiosarcoma of the Liver France

Unknown status·CCentre Oscar Lambret·N/A·NCT01786889·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for blood and urine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — blood and urine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for blood and urine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Oscar Lambret company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentre Oscar Lambret

blood and urine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Angiosarcoma1 trial

References

Drug Info

Quick Facts

Related News